Sanofi (NASDAQ:SNY) Stock Position Decreased by Fmr LLC

Fmr LLC lowered its holdings in Sanofi (NASDAQ:SNY) by 43.4% during the third quarter, HoldingsChannel.com reports. The fund owned 8,617,617 shares of the company’s stock after selling 6,596,662 shares during the period. Fmr LLC’s holdings in Sanofi were worth $496,633,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of SNY. The Manufacturers Life Insurance Company lifted its holdings in shares of Sanofi by 408.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 160,339 shares of the company’s stock worth $9,244,000 after purchasing an additional 128,811 shares during the last quarter. Bank of Montreal Can lifted its stake in Sanofi by 10.0% in the third quarter. Bank of Montreal Can now owns 256,438 shares of the company’s stock valued at $14,784,000 after buying an additional 23,352 shares during the last quarter. Independent Advisor Alliance acquired a new position in shares of Sanofi during the third quarter valued at $202,000. Bank of Hawaii grew its position in shares of Sanofi by 10.4% during the third quarter. Bank of Hawaii now owns 22,765 shares of the company’s stock worth $1,312,000 after acquiring an additional 2,148 shares during the last quarter. Finally, Capital Investment Counsel LLC increased its holdings in shares of Sanofi by 5.5% in the 3rd quarter. Capital Investment Counsel LLC now owns 66,487 shares of the company’s stock worth $3,832,000 after acquiring an additional 3,468 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on SNY shares. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

SNY stock opened at $48.49 on Friday. The company has a 50-day simple moving average of $52.80 and a 200 day simple moving average of $52.11. The company has a market capitalization of $123.06 billion, a P/E ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period last year, the firm posted $2.55 earnings per share. The business’s revenue was up 12.3% on a year-over-year basis. Sell-side analysts predict that Sanofi will post 4.29 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.